Yang Wei, Ye Yumei, Cai Yan, Wang Guiyan, Wang Menghao, Zhang Xiaodan
Department of TCM, Seventh People's of Shanghai University of TCM, Shanghai 200137, China.
Evid Based Complement Alternat Med. 2022 Jun 2;2022:4311031. doi: 10.1155/2022/4311031. eCollection 2022.
To investigate the improvement of cognitive function and inflammatory response in perimenopausal patients with MCI by kidney-tonifying, blood-activating, and mind-nourishing.
80 perimenopausal patients with MCI who met the diagnostic criteria were divided into a therapy group ( = 40) and a control group ( = 40) according to the treatment method. The control group was given nimodipine (Bayer Pharmaceuticals) 30 mg, 3 times/day orally, while the therapy group was given a decoction of self-prepared Ningshen prescription on the top of the control group (glossy privet fruit, mulberry, aizoon stonecrop, dan-shen root, tuber fleeceflower stem, cyperus rotundus, citron). Patients in the 2 groups were assessed on the MocA scale, ADL scale, and TCM symptom score before and after 2 months of treatment, respectively, to observe whether there was any change in the scale scores and in the levels of inflammatory factors (hs-CRP, Hcy, and IL-1) Pre- and posttherapy in the 2 groups. Observe the improvement of clinical symptoms and their safety in both groups (liver and kidney function indicators such as ALT, AST and Cr, dizziness, headache, decrease in blood pressure, flushing, and gastrointestinal reactions).
The efficacy of the therapy group was better than that of the control group; the MocA scale and ADL scale scores improved and the TCM symptom score decreased in both groups posttherapy, with the MocA scale and ADL scale scores improving more and the TCM symptom score decreasing more in the therapy group compared with the control group during the same period ( < 0.05). The serum levels of hs-CRP, Hcy, and IL-1 decreased in both groups posttherapy, with the serum levels of hs-CRP, Hcy, and IL-1 decreasing more in the therapy group compared to the control group during the same period ( < 0.05). The difference in adverse events between the two groups was not statistically significant when compared by a chi-square test ( > 0.05). The differences in ALT, AST, and Cr levels between the control group and the treatment group before and after treatment were not significant ( > 0.05).
Ning Shen prescription can effectively prevent the continued development of cognitive dysfunction in perimenopausal patients with MCI, delay its natural course, and can improve the patients' ability to perform daily activities and improve their TCM symptoms.
探讨补肾活血养心法对围绝经期轻度认知功能障碍（MCI）患者认知功能及炎症反应的改善作用。
将80例符合诊断标准的围绝经期MCI患者按治疗方法分为治疗组（n = 40）和对照组（n = 40）。对照组口服尼莫地平（拜耳制药）30 mg，每日3次，治疗组在对照组基础上加服自拟宁神方（女贞子、桑椹、景天三七、丹参、夜交藤、香附、佛手）水煎剂。分别于治疗2个月前后对两组患者进行蒙特利尔认知评估量表（MocA）、日常生活活动能力量表（ADL）评分及中医症状评分，观察量表评分及炎症因子（hs-CRP、Hcy、IL-1）水平在治疗前后的变化。观察两组临床症状改善情况及安全性（谷丙转氨酶、谷草转氨酶、肌酐等肝肾功能指标，头晕、头痛、血压下降、面部潮红、胃肠道反应）。
治疗组疗效优于对照组；两组治疗后MocA量表和ADL量表评分均升高，中医症状评分均降低，且治疗组MocA量表和ADL量表评分升高幅度及中医症状评分降低幅度均大于对照组同期（P < 0.05）。两组治疗后血清hs-CRP、Hcy、IL-1水平均降低，且治疗组血清hs-CRP、Hcy、IL-1水平降低幅度大于对照组同期（P < 0.05）。两组不良事件经卡方检验比较差异无统计学意义（P > 0.05）。对照组与治疗组治疗前后谷丙转氨酶、谷草转氨酶、肌酐水平比较差异无统计学意义（P > 0.05）。
宁神方能够有效阻止围绝经期MCI患者认知功能障碍的继续发展，延缓其自然病程，且能提高患者日常生活活动能力，改善中医症状。
